Ovarian Cancer
The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer (VB-111-701 / GOG-3018)
- Details
ClinicalTrials.gov ID:
NCT03398655
Diagnosis Type:
NA
USOR Number:
- Address
,
P: